T he human genome has been cracked wide open in recent years and is spilling many of its secrets. More than 100 genome wide association studies have been conducted for scores of hu man diseases, identifying hun dreds of polymorphisms that are widely seen to influence disease risk. After many years in which the study of complex human traits was mired in false claims and methodologic inconsistencies, ge nomics has brought not only com prehensive representation of com mon variation but also welcome rigor in the interpretation of sta tistical evidence. Researchers now know how to properly account for most of the multiple hypothesis testing involved in mining the ge nome for associations, and most reported associations reflect real biologic causation. But do they matter?
Unfortunately, most common gene variants that are implicated by such studies are responsible for only a small fraction of the genetic variation that we know exists. This observation is par ticularly troubling because the studies are largely comprehensive in terms of common singlenucle otide polymorphisms (SNPs), the genomic markers that are geno typed and with which disease as sociations are tested. We're find ing the biggest effects that exist for this class of genetic variant, and common variation is packing much less of a phenotypic punch than expected. Some experts em phasize that small effect sizes don't necessarily mean that a gene variant is of no interest or use. Effect size is a function of what a variant does: it may change only slightly a gene's expression or a protein's function. The gene's pathway, however, may be deci sive for a particular condition, or pharmacologic action on the same protein may produce much larger effects in controlling disease. These arguments are reasonable, as far as they go, and there are supporting examples, such as a polymorphism of modest effect in PPARG, a gene that encodes a drug target for diabetes.
But the arguments hold only if common genetic variation im plicates a manageable number of genes. If effect sizes were so small as to require a large chunk of the genome to explain the genet ic component of a disorder, then no guidance would be provided: in pointing at everything, genet ics would point at nothing. To assess whether effect sizes are too small in this sense, consider two examples of complex human traits -type 2 diabetes and height. In their recent review, Manolio et al. 1 described seven gene variants that influence the risk of type 2 diabetes. In addition to these variants, the one with the strongest effect on familial aggre gation is in the TCF7L2 gene.
One way to assess a variant's effect is by comparing the dis ease risk of the sibling of an af fected person with that in the general population (sibling rela tive risk). The TCF7L2 variant is associated with a sibling relative risk for type 2 diabetes of only about 1.02, whereas the overall risk of disease among siblings of affected persons is three times that in the general population. If the human genome carried scores of variants with such effects, they would collectively generate a sub stantial sibling relative risk. Un fortunately, we now know this is not the case: the contribution of common risk alleles to familial clustering falls off dramatically after TCF7L2 and appears to be come asymptotic at a level only marginally above 1 (see Panel A of the figure). 2 It seems likely, then, that an unreasonably large num ber of such variants would be re quired to account for the genetic component of diabetes risk, even if the sibling relative risk values overestimate the genetic compo nent of disease.
A more quantitative evaluation is available for height, for which Weedon et al. 3 identified 20 poly morphisms. Using a replication sample set, they estimated that collectively, the variants they stud ied explain less than 3% of the population variation in height (see Panel B of the figure). To esti mate the full distribution of ef fect sizes (including those of vari ants not yet discovered), one could assume an exponential distribu tion and estimate the parame ters from the observed data. The predicted effect of the nth SNP is calculated as follows:
Effect size of nth SNP = k + a × Exp[−bn], in which k = 0.0008, a = 0.35, and b = 0.1152. To estimate the num ber of SNPs required to explain 80% of population variation in height (the most common esti mate of height's heritability), this equation can be integrated and solved numerically. The answer is that approximately 93,000 SNPs are required to explain 80% of the population variation in height. In the fitted distribution, the con stant term (0.0008) can be viewed as the predicted smallest effect size in the genome, given the 20 strongest effects already identi fied. The resulting integral can be considered valid only over the range of 1 to approximately 93,000, at which point all heritability would be explained. I assume that all SNPs yet to be discovered have weaker effect sizes than the weakest so far found. Though the strongest SNP may have been found, many SNPs could remain unidentified in the range of the lower effects that have been determined. If such SNPs are accounted for, fewer SNPs will be required to explain a given proportion of variance. The sample sizes that have been studied for height, however, range from 14,000 to 34,000. At the lower sample size, the power of detection is 90% for the largest effect size; for effect sizes as small as 0.05%, the largest sam ple size provides a 10% chance of detection. Even if we conser vatively assume that all remaining unidentified variants influencing height each explained as much as 0.05% of the variation, 1500 such variants would be required to ex plain the missing heritability. These calculations also assume that the effects of "height SNPs" are additive. If variants show meaningful interactions, a some what stronger genetic effect could emerge among variants with small individual effect sizes. But only dramatic departures from these assumptions would allow a manageable number of common SNPs to account for a sizable frac tion of the heritability of height.
If common variants are respon sible for most genetic compo nents of type 2 diabetes, height, and similar traits, then genetics will provide relatively little guid ance about the biology of these conditions, because most genes are "height genes" or "type 2 dia betes genes." It seems much more likely, however, that most genetic control is due to rarer variants, either singlesite or structural, that are not represented in the current studies and that have considerably larger effects than common variants. Whether these "rarer" variants are only slightly below the threshold for detection on current platforms or substan tially more rare remains to be seen. If, however, rarer variants are primarily responsible for the missing heritability, we may yet identify a manageable number of genes and pathways.
Either way, it's hard to have any enthusiasm for conducting genome scans with the use of ever larger cohorts after a study of the first several thousand sub jects has identified the strongest determinants among common variants. These initial studies for a given common disease are worth doing, since common variants do appear to explain a sizable frac tion of the heritability of certain conditions -notably, exfoliation glaucoma, macular degeneration, and Alzheimer's disease. Beyond studies of this size, however, we enter the flat or declining part of the effectsize distributions, where there are probably either no more common variants to dis cover or no more that are worth discovering.
By contrast, genome scans have not yet been performed in search of variants involved in many re sponses to drugs or infectious agents, even though there are examples in both categories of common polymorphisms whose effects dwarf those seen for type 2 diabetes and many other diseas es. For example, when exposed to the antiHIV drug abacavir, a hy persensitivity reaction develops in more than half the carriers of the HLAB*5701 allele, whereas such a reaction occurs in less than 5% of patients without this allele. 4 Similarly, just three com mon variants are sufficient to ex plain 14% of the population vari ation in HIV1 viral load. 5 But with traits such as height or type 2 diabetes, it seems that an inordinate number of common SNPs would be needed to account for a sizable fraction of herita bility. Indeed, it's possible that the way genome scans are being interpreted actually overestimates the contributions of common variants. Most variants that have been identified to date are mark ers, not causal variants, and are generally assumed to reflect the effects of some other, asyet unidentified common variant. Another possibility, however, is that some of the associations that are credited to common variants are actually synthetic associations involving multiple rare variants that occur, by chance, more fre quently in association with one allele at a common SNP than with the other. In this case, as well, genome scans will overesti mate the contribution of common variants.
The apparently modest effect of common variation on most hu man diseases and related traits probably reflects the efficiency of natural selection in prohibiting in creases in diseaseassociated vari ants in the population. I believe attention should shift from ge nome scans of ever larger samples to studies of rarer variants of larger effect. Effectively search ing the full human genome for rare variants will require not only sequencing capacity but also thoughtful selection of the most appropriate groups of individ ual genomes to resequence and thoughtful evaluation and prior itization of the many rare vari ants identified. There's no guar antee that associations with rare variants will point directly to cau sation. Nevertheless, the limited role of common variation in many highly heritable diseases argues strongly that there are many rare variants to be found, and it seems reasonable to hope that some of them will suggest novel therapeu tic targets or help in the design of personalized prevention or treatment regimens.
These conclusions imply no criticism of the strikingly success ful efforts to represent common variation and relate it to common diseases. Indeed, I share the view Hirschhorn presents in his Per spective article (pages 1699-1701) that the early skeptics have been proved wrong about genome wide association studies in most de tails: patterns of linkage disequi librium are sufficiently consistent to allow efficient representation of common variation with the use of "tagging" SNPs, and secure associations between polymor phisms and diseases were rapidly and easily identified. But even though genomewide association studies have worked better and faster than expected, they have not explained as much of the genetic component of many dis eases and conditions as was an ticipated. We must therefore turn more sharply toward the study of rare variants.
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